Johnson & Johnson today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback